PE ratio relative to earnings growth — is the valuation justified?
—
PEG Ratio
Negative earnings — PE and PEG ratios are not meaningful
—
Current Price
$38.37
TTM EPS
$-4.36
P/E Ratio
—
Growth Rate
—
N/A
Sector
Healthcare
Biotechnology
Calculated
8/18/2026
11:08:36 AM
PEG Ratio Unavailable
Insufficient price/EPS data
Peer Comparison
Sample Size
2 peers
Industry Median PEG
0.52
25th Percentile
0.17
75th Percentile
0.88
Symbol
Company
PEG
P/E
Growth
vs CLDX
ACAD
ACADIA Pharmaceuticals Inc.
0.17
11.7
69.3%
—
HALO
Halozyme Therapeutics, Inc.
0.88
19.9
22.7%
—
How to Interpret PEG Ratio
PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.
PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."
PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.
Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.
